MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 60-year-old man with a prior anterior ST-elevation myocardial infarction and reduced left ventricular ejection fraction (30%) is seen in cardiology clinic. He is clinically euvolaemic. His current medications are ramipril, bisoprolol and spironolactone at guideline doses. According to contemporary Canadian heart failure guidance, which additional class of medication should now be prioritised to optimise his foundational pharmacotherapy for HFrEF?